> A prospective, randomized open-label, blinded end-point (PROBE), investigator-initiated, international study that will determine the efficacy and safety of edoxaban compared with standard of care (either no antithrombotic therapy or antiplatelet monotherapy) for stroke prevention in high-risk AF (CHA2DS2-VASc score ?2) patients and previous intracranial haemorrhage.
> ENRICH-AF will provide definitive data on the efficacy and safety of edoxaban compared to non- anticoagulant medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) in high- risk AF patients with previous intracranial hemorrhage
Sample Size: 1200 patients from 22 countries & 200 patients from 15-20 centers in India.
Study Update: Currently, 09 patients randomized into the trial globally and in India, regulatory submissions on-going.
Updated as of 2nd Sep, 2020